Endometrial hyperplasia and endometriosis are not the same condition. They share a root word because both involve the endometrium (the lining of the uterus), but they differ in where the problem occurs, what drives it, how it feels, and what risks it carries. Endometrial hyperplasia is an overgrowth of the uterine lining itself, while endometriosis involves tissue similar to that lining growing outside the uterus entirely.
Where Each Condition Occurs
Endometrial hyperplasia happens inside the uterus. The lining that normally thickens each month in preparation for pregnancy grows too thick and doesn’t shed properly. The tissue stays where it belongs but accumulates beyond normal levels.
Endometriosis is essentially the opposite scenario in terms of location. Tissue similar to the uterine lining grows outside the uterus, most often on the ovaries, fallopian tubes, and the tissue lining the pelvis. It can also affect nearby organs like the bowel and bladder, and in rare cases, it appears beyond the pelvic area altogether. This misplaced tissue still responds to hormonal cycles. It thickens, breaks down, and bleeds each month, but because it has no way to exit the body, it becomes trapped. The surrounding tissue gets irritated, scar tissue forms, and bands of fibrous tissue called adhesions can cause pelvic organs to stick together. When endometriosis affects the ovaries, fluid-filled cysts called endometriomas can develop.
What Causes Each One
Both conditions involve hormonal imbalance, but in different ways. Endometrial hyperplasia is driven by too much estrogen relative to progesterone. In a normal cycle, estrogen builds up the uterine lining during the first half of the month, then progesterone steps in during the second half to stop that growth and trigger the process that prepares the lining either for implantation or shedding. When progesterone is insufficient or absent, estrogen keeps stimulating the lining to grow unchecked.
Several things create this imbalance. Polycystic ovary syndrome (PCOS) is a major risk factor because women with PCOS often don’t ovulate regularly, meaning progesterone production is low or absent in many cycles. Obesity plays a significant role too, since fat tissue produces estrogen. Research in women with PCOS has found that higher body fat mass is an independent risk factor for developing endometrial hyperplasia, with strong correlations to insulin resistance and disrupted metabolism of glucose, lipids, and uric acid. The transition to menopause, when ovulation becomes irregular, and estrogen-only hormone therapy without progesterone also increase risk.
Endometriosis has a more complex and less fully understood origin. The leading theory is that menstrual blood flows backward through the fallopian tubes into the pelvic cavity, depositing endometrial cells that then implant and grow. But not every woman who experiences this retrograde flow develops endometriosis, so immune system differences, genetics, and local hormonal factors all seem to play a role. In endometriosis tissue, cells develop a resistance to progesterone and become dominated by estrogen signaling, which fuels continued growth and inflammation in the lesions.
How Symptoms Differ
The hallmark symptom of endometrial hyperplasia is abnormal uterine bleeding. This can show up as periods that are heavier or longer than usual, bleeding between periods, or any uterine bleeding after menopause. Pain is not typically a central feature. The condition is often discovered because of irregular or excessive bleeding that prompts a medical visit.
Endometriosis, by contrast, is defined by pain. It is the most common cause of secondary dysmenorrhea, meaning severe menstrual cramps that develop after years of relatively normal periods. The pain often extends beyond menstruation itself, showing up during ovulation, sex, bowel movements, or urination. Some women experience chronic pelvic pain throughout the month. Infertility is another common way endometriosis comes to attention. While bleeding irregularities can occur, pain and its impact on physical and psychological well-being are what most characterize the condition.
How Each Is Diagnosed
The diagnostic paths for these two conditions are quite different. Endometrial hyperplasia is diagnosed by sampling the uterine lining directly. A thin instrument is passed through the cervix to collect tissue, which is then examined under a microscope. An ultrasound showing unusually thick lining often prompts this biopsy, but the tissue sample is what confirms the diagnosis and determines the type.
Endometriosis is harder to pin down. The gold standard for diagnosis has been laparoscopy, a minimally invasive surgery where a small camera is inserted through the abdomen to visually inspect pelvic organs. Ideally, at least one suspicious lesion is biopsied for confirmation, because endometriosis can take on many different appearances and visual inspection alone can miss or misidentify it. Under a microscope, a diagnosis requires finding at least two hallmark features: endometrial-type glands, stroma (supporting tissue), or iron-containing immune cells that indicate old bleeding. Imaging tools like ultrasound and MRI can detect larger forms like ovarian endometriomas, but smaller or superficial lesions often escape detection without surgery.
Cancer Risk and Classification
This is one of the most important distinctions between the two conditions. Endometrial hyperplasia has a direct, well-quantified relationship with uterine cancer. The WHO classifies it into two categories: hyperplasia without atypia, and atypical hyperplasia. The difference matters enormously.
Hyperplasia without atypia carries very low cancer risk, under 1%. The cells are overgrown but still look normal. Atypical hyperplasia is a different story. Between 25% and 33% of women diagnosed with atypical hyperplasia already have a coexisting uterine cancer at the time of diagnosis, and among those who don’t receive effective treatment, 40% to 50% may eventually develop one. Atypical hyperplasia shares many of the same genetic mutations found in endometrial cancer and is considered a direct precursor to it.
Endometriosis carries a smaller and less direct cancer risk. It has been associated with certain subtypes of ovarian cancer, particularly endometrioid and clear cell types. The strongest link is seen in women with deep infiltrating endometriosis or ovarian endometriomas. However, the overall absolute risk remains low, and endometriosis is not classified as a precancerous condition the way atypical hyperplasia is.
Treatment Approaches
Treatment reflects the different nature of each condition. For endometrial hyperplasia without atypia, the goal is restoring the hormonal balance that the uterus lost. Progestin therapy, delivered as a pill, injection, or intrauterine device, counteracts the estrogen dominance and allows the lining to return to normal. Many women see their hyperplasia resolve within several months of treatment. Addressing underlying causes like obesity or PCOS also plays a role. For atypical hyperplasia, hysterectomy is often recommended because of the high cancer risk, especially for women who are done having children.
Endometriosis treatment centers on managing pain and preserving fertility when desired. Hormonal therapies that suppress ovulation and reduce estrogen can slow the growth of endometriosis tissue and relieve symptoms. When medication isn’t enough, surgery to remove or destroy endometriosis lesions and adhesions can provide relief, though the condition has a tendency to recur. For severe cases that don’t respond to other treatments, hysterectomy with removal of the ovaries may be considered, but this is a last resort because of the permanent hormonal consequences.
Can You Have Both?
Yes, though it’s not especially common. Because both conditions involve disrupted estrogen and progesterone signaling, some of the same hormonal environments can contribute to both. A woman with significant estrogen dominance could theoretically develop thickened uterine lining and endometriosis lesions simultaneously. The two conditions are diagnosed and managed independently, so having one doesn’t rule out or automatically lead to the other. If you’re experiencing both abnormal bleeding and chronic pelvic pain, it’s worth discussing the possibility of overlapping conditions with your provider.